Progyny Inc (PGNY)
Official siteHEALTHCARE • HEALTHCARE PLANS • NASDAQ
Market Cap: $2.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Progyny Inc (PGNY) Earnings: Report Dates and Results
Progyny (PGNY) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Progyny reported EPS of $0.31, above the $0.27 estimate. It beat the EPS estimate in each of the last 23 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PGNY has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 150.0% above the $0.14 reported for the quarter ended Dec 31, 2025.
PGNY Earnings Call
The latest PGNY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, PGNY beat 28 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $341.25M, up 8.9% from $313.35M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.31 | $0.27 | N/A | +14.81% | Beat | -31.1% | 9 | 1 up, 6 down | Nov 4, 2026 | $341.25M |
| Jun 30, 2026 | $0.34 | $0.28 | N/A | +21.43% | Beat | +78.9% | 8 | 0 up, 0 down | Aug 6, 2026 | $350.51M |
| Mar 31, 2026 | $0.50 | $0.44 | $0.43 - $0.45 | +13.64% | Beat | +4.2% | 8 | 0 up, 5 down | May 7, 2026 | $328.50M |
| Dec 31, 2025 | $0.14 | $0.13 | N/A | +7.69% | Beat | -66.7% | 8 | 2 up, 0 down | Feb 26, 2026 | $318.40M |
| Sep 30, 2025 | $0.45 | $0.39 | $0.38 - $0.40 | +15.38% | Beat | +12.5% | 7 | 4 up, 1 down | Nov 6, 2025 | $313.35M |
| Jun 30, 2025 | $0.19 | $0.17 | N/A | +11.76% | Beat | -55.8% | 6 | 3 up, 0 down | Aug 7, 2025 | $332.87M |
| Mar 31, 2025 | $0.48 | $0.45 | $0.44 - $0.46 | +6.67% | Beat | +23.1% | 7 | 4 up, 0 down | May 8, 2025 | $324.04M |
| Dec 31, 2024 | $0.42 | $0.37 | $0.33 - $0.43 | +13.51% | Beat | +223.1% | 6 | 2 up, 0 down | Feb 27, 2025 | $298.43M |
| Sep 30, 2024 | $0.40 | $0.37 | N/A | +8.11% | Beat | +150.0% | 9 | 0 up, 0 down | Nov 12, 2024 | $286.63M |
| Jun 30, 2024 | $0.43 | $0.40 | N/A | +7.50% | Beat | +186.7% | 10 | 0 up, 0 down | Aug 6, 2024 | $304.09M |
| Mar 31, 2024 | $0.39 | $0.35 | N/A | +11.43% | Beat | +116.7% | 9 | 0 up, 0 down | May 9, 2024 | $278.08M |
| Dec 31, 2023 | $0.13 | $0.11 | $0.07 - $0.19 | +18.18% | Beat | +333.3% | 10 | 0 up, 0 down | Feb 27, 2024 | $269.94M |
| Sep 30, 2023 | $0.16 | $0.11 | $0.09 - $0.17 | +45.45% | Beat | +23.1% | 7 | 0 up, 0 down | Nov 7, 2023 | $280.89M |
| Jun 30, 2023 | $0.15 | $0.10 | $0.09 - $0.14 | +50.00% | Beat | +66.7% | 7 | 0 up, 0 down | Aug 3, 2023 | $279.37M |
| Mar 31, 2023 | $0.18 | $0.08 | $0.06 - $0.08 | +125.00% | Beat | +260.0% | 6 | 1 up, 0 down | May 8, 2023 | $258.39M |
| Dec 31, 2022 | $0.03 | $0.01 | -$0.03 - $0.03 | +200.00% | Beat | -80.0% | 6 | 0 up, 1 down | Feb 27, 2023 | $214.32M |
| Sep 30, 2022 | $0.13 | $0.03 | $0.01 - $0.15 | +333.33% | Beat | -23.5% | 7 | 0 up, 0 down | Nov 3, 2022 | $205.37M |
| Jun 30, 2022 | $0.09 | $0.01 | N/A | +800.00% | Beat | -52.6% | N/A | 0 up, 0 down | Aug 4, 2022 | $195.00M |
| Mar 31, 2022 | $0.05 | -$0.02 | -$0.02 - $0.10 | +350.00% | Beat | -66.7% | 5 | 0 up, 0 down | May 5, 2022 | $172.22M |
| Dec 31, 2021 | $0.15 | $0.04 | $0.02 - $0.07 | +275.00% | Beat | +1400.0% | 5 | 0 up, 1 down | Feb 28, 2022 | $127.55M |
| Sep 30, 2021 | $0.17 | $0.06 | $0.05 - $0.08 | +183.33% | Beat | +142.9% | 5 | N/A | Nov 4, 2021 | $122.28M |
| Jun 30, 2021 | $0.19 | $0.09 | $0.08 - $0.09 | +111.11% | Beat | N/A | 3 | N/A | Aug 5, 2021 | $128.65M |
| Mar 31, 2021 | $0.15 | $0.09 | N/A | +66.67% | Beat | +200.0% | 3 | N/A | May 6, 2021 | $122.13M |
| Dec 31, 2020 | $0.01 | $0.06 | $0.05 - $0.06 | -83.33% | Miss | 0.0% | 3 | N/A | Feb 24, 2021 | $100.30M |
| Sep 30, 2020 | $0.07 | $0.06 | $0.04 - $0.06 | +16.67% | Beat | +133.3% | 5 | N/A | Nov 5, 2020 | $98.93M |
| Jun 30, 2020 | -$0.01 | -$0.02 | -$0.05 - -$0.01 | +50.00% | Beat | -133.3% | 5 | N/A | Aug 5, 2020 | $64.61M |
| Mar 31, 2020 | $0.05 | $0.02 | -$0.01 - $0.06 | +150.00% | Beat | N/A | 4 | N/A | May 12, 2020 | $81.02M |
| Dec 31, 2019 | $0.01 | $0.02 | $0.01 - $0.06 | -50.00% | Miss | N/A | 4 | N/A | Mar 5, 2020 | $65.12M |
| Sep 30, 2019 | $0.03 | $0.02 | $0.02 - $0.02 | +50.00% | Beat | N/A | 4 | N/A | Oct 25, 2019 | $61.20M |
| Jun 30, 2019 | $0.03 | $0.02 | N/A | +50.00% | Beat | N/A | N/A | N/A | Aug 2, 2019 | $56.17M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.26, down 23.2% from the year before. It was $0.07 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.26 | -23.2% |
| Dec 31, 2024 | $1.64 | +164.5% |
| Dec 31, 2023 | $0.62 | +106.7% |
| Dec 31, 2022 | $0.30 | -54.5% |
| Dec 31, 2021 | $0.66 | +450.0% |
| Dec 31, 2020 | $0.12 | +71.4% |
| Dec 31, 2019 | $0.07 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,448 | 14 | |
| 2026Q2 | Jun 30, 2026 | 5,727 | 13 | |
| 2026Q1 | Mar 31, 2026 | 5,958 | 12 | |
| 2025Q4 | Dec 31, 2025 | 6,745 | 12 | |
| 2025Q3 | Sep 30, 2025 | 5,587 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,907 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,116 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,918 | 14 |
2026Q3 Earnings Call
Opening remarks
James Hart Host Thank you, Sylvie, and good afternoon, everyone. Welcome to our third quarter conference call. With me today are Pete Anevski, CEO of Progyny, and Mark Livingston, CFO. We will begin with some prepared remarks before we open the call for your questions. Before we begin, I'd like to remind you that our comments and responses to your questions today reflect management's views as of today only and will include statements related to our financial outlook for both the fourth quarter and full year 2026 and the assumptions and drivers underlying such guidance; the demand for our solutions; our expectations for our selling season for 2027 launches; anticipated employment levels of our clients and the industries we serve; the timing of client decisions; our expected utilization rates and mix; the potential benefits of our solution; our ability to acquire new clients and retain and upsell existing clients; our market opportunity and our business strategy, plans, goals and expectations concerning our market position, future operations and other financial and operating information, which are forward-looking statements under the federal securities law. Actual results may differ materially from those contained in or implied by these forward-looking statements due to risks and uncertainties associated with our business as well as other important factors. For a discussion of the material risks, uncertainties, assumptions and other important factors that could impact our actual results, please refer to our SEC filings and today's press release, both of which can be found on our Investor Relations website. Any forward-looking statements that we make on this call are based on assumptions as of today, and we undertake no obligation to update these statements as a result of new information or future events. During the call, we will also refer to non-GAAP financial measures, such as adjusted EBITDA. More information about these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, is available in the press release, which is available at investors.progyny.com. I would now like to turn the call over to Pete.
Peter Anevski CEO Thanks, Jamie, and thanks, everyone, for joining us this afternoon. I'm pleased to report that Progyny had a strong quarter, resulting in record revenue and profitability for the third quarter as well as the continued generation of significant cash flow, which we're using both to invest in the business for future growth and return value to our shareholders through meaningful share repurchase activity. As the fourth quarter begins, member engagement remains healthy. Given that, as well as our strong performance over the first nine months of the year, we're pleased to be in a position to raise the midpoint of our full-year guidance.
Frequently Asked Questions About PGNY
When is Progyny's next earnings date?
Progyny's next earnings report is expected for Feb 24, 2027.
Did PGNY beat earnings estimates last quarter?
Yes. Progyny reported EPS of $0.31 for the quarter ended Sep 30, 2026, above the $0.27 estimate, a 14.81% surprise.
What EPS do analysts expect from PGNY next quarter?
The consensus EPS estimate for Progyny for the quarter ending Dec 31, 2026 is $0.35 from 14 analysts, with estimates from $0.30 to $0.40.
How often does PGNY beat earnings estimates?
Progyny beat the EPS estimate in each of the last 23 quarters, with an average surprise of +116.96%.
PGNY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors